Exploring why some colorectal cancers resist treatment targeting KRAS
Understanding intrinsic resistance to direct KRAS inhibition in colorectal cancers
This study is looking into why some colorectal cancers don’t respond well to treatments that target the KRAS gene, and it aims to find new ways to make these treatments work better for patients who need more effective options.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11001173 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind why colorectal cancers often do not respond to treatments that target the KRAS gene. The team is using advanced techniques, including proteomics and kinome-wide knockdown, to identify specific kinases that may help overcome this resistance. By understanding the signaling pathways involved, the researchers aim to find ways to enhance the effectiveness of KRAS inhibitors in colorectal cancer patients. This could lead to more effective treatment options for those who currently have limited responses to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic colorectal cancer, particularly those with KRAS mutations who have not responded well to existing treatments.
Not a fit: Patients with colorectal cancer who do not have KRAS mutations or those whose cancer is not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for colorectal cancer patients who are resistant to current KRAS-targeting therapies.
How similar studies have performed: While there have been successful approaches targeting KRAS in other cancers, this specific investigation into colorectal cancer resistance mechanisms is relatively novel.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Gordan, John D — University of California, San Francisco
- Study coordinator: Gordan, John D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.